PPA
AGIO icon

Parametric Portfolio Associates’s Agios Pharmaceuticals AGIO Stock Holding History

Parametric Portfolio Associates’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$782K Sell
26,864
-22,611
-46% -$691K ﹤0.01% 2894
2021
Q4 		$1.63M Sell
49,475
-25,649
-34% -$1.03M ﹤0.01% 2568
2021
Q3 		$3.47M Sell
75,124
-58,588
-44% -$2.83M ﹤0.01% 2087
2021
Q2 		$7.37M Sell
133,712
-5,039
-4% -$282K ﹤0.01% 1602
2021
Q1 		$7.17M Sell
138,751
-18,102
-12% -$896K ﹤0.01% 1912
2020
Q4 		$6.8M Buy
156,853
+14,794
+10% +$585K ﹤0.01% 1863
2020
Q3 		$4.97M Sell
142,059
-24,625
-15% -$1.08M ﹤0.01% 1897
2020
Q2 		$8.91M Buy
166,684
+55,876
+50% +$2.59M 0.01% 1475
2020
Q1 		$3.93M Buy
110,808
+18,864
+21% +$872K ﹤0.01% 1919
2019
Q4 		$4.39M Buy
91,944
+46,241
+101% +$1.75M ﹤0.01% 2154
2019
Q3 		$1.48M Sell
45,703
-9,501
-17% -$393K ﹤0.01% 2812
2019
Q2 		$2.75M Buy
55,204
+7,709
+16% +$412K ﹤0.01% 2444
2019
Q1 		$3.2M Buy
47,495
+5,167
+12% +$301K ﹤0.01% 2323
2018
Q4 		$1.95M Buy
42,328
+4,035
+11% +$249K ﹤0.01% 2603
2018
Q3 		$2.95M Buy
38,293
+2,549
+7% +$205K ﹤0.01% 2425
2018
Q2 		$3.01M Buy
35,744
+10,958
+44% +$956K ﹤0.01% 2373
2018
Q1 		$2.03M Buy
24,786
+2,206
+10% +$171K ﹤0.01% 2608
2017
Q4 		$1.29M Buy
22,580
+1,015
+5% +$63.9K ﹤0.01% 2877
2017
Q3 		$1.44M Buy
21,565
+1,200
+6% +$72.1K ﹤0.01% 2801
2017
Q2 		$1.05M Sell
20,365
-3,237
-14% -$165K ﹤0.01% 2963
2017
Q1 		$1.38M Buy
23,602
+1,755
+8% +$84.1K ﹤0.01% 2690
2016
Q4 		$912K Buy
21,847
+364
+2% +$19.1K ﹤0.01% 2891
2016
Q3 		$1.14M Sell
21,483
-1,432
-6% -$62.4K ﹤0.01% 2724
2016
Q2 		$960K Buy
22,915
+6,354
+38% +$314K ﹤0.01% 2858
2016
Q1 		$672K Buy
16,561
+9,581
+137% +$410K ﹤0.01% 3170
2015
Q4 		$453K Sell
6,980
-2,723
-28% -$179K ﹤0.01% 3317
2015
Q3 		$685K Buy
9,703
+6,213
+178% +$607K ﹤0.01% 2556
2015
Q2 		$388K Buy
3,490
+1,199
+52% +$129K ﹤0.01% 3423
2015
Q1 		$216K Buy
+2,291
New +$257K ﹤0.01% 3724

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Parametric Portfolio Associates's AGIO Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Agios Pharmaceuticals (AGIO) stake by 46% in Q1 2022, selling an estimated $691K and leaving 26,864 shares worth $782K. The position accounts for ﹤0.01% of the portfolio, ranked #2894.

Parametric Portfolio Associates first reported a position in AGIO in Q1 2015 and has held it in 29 quarters since. The position peaked at $8.91M in Q2 2020. 161 funds tracked by Wall St. Rank hold AGIO as of Q1 2022.

  • Parametric Portfolio Associates held 26,864 shares of Agios Pharmaceuticals worth $782K as of Q1 2022.
  • Parametric Portfolio Associates sold 22,611 Agios Pharmaceuticals shares in Q1 2022, an estimated $691K.
  • Agios Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2894 holding.
  • Parametric Portfolio Associates first reported a position in Agios Pharmaceuticals in Q1 2015 and has held it in 29 quarters since.
  • Parametric Portfolio Associates's Agios Pharmaceuticals position peaked at $8.91M in Q2 2020.
  • 161 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.